Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. (NASDAQ: ADTX) regularly issues news and regulatory updates that describe its activities as a social innovation platform accelerating promising health innovations. Company news often highlights developments across its programs in immune health, precision diagnostics, autoimmunity, cancer and early disease detection, infectious diseases, and women’s health, as well as platform-level initiatives such as the bitXbio™ strategy.
Recent announcements have focused on the evolution of Aditxt’s bitXbio™ framework, which the company describes as a transformational approach intended to connect public markets, blockchain and Web3 concepts, digital asset treasuries, and life sciences operating companies. News items have discussed proxy proposals related to an Employee Stock Purchase Plan, equity incentive plan changes, and a non-binding advisory vote on a proposed name change from “Aditxt, Inc.” to “bitXbio, Inc.”
Updates about Aditxt’s subsidiaries and ventures are another recurring theme. For example, the company has reported on Adimune, a wholly owned subsidiary developing a DNA-based therapeutic platform to reprogram the immune system, including information on its patent portfolio and plans related to first-in-human trials for conditions such as type 1 diabetes and stiff person syndrome. News has also covered Pearsanta, Aditxt’s precision diagnostics subsidiary, including the start of enrollment in a clinical study of the Mitomic® Endometriosis Test (MET™) and Pearsanta’s work with Mitomic® and Adductomics testing platforms.
Capital markets and corporate governance developments appear frequently in Aditxt’s news flow. The company has issued press releases about a 1-for-113 reverse stock split intended to address Nasdaq’s minimum bid price requirement, as well as proxy statements and special meetings to approve issuances of common stock underlying preferred stock and warrants, an Employee Stock Purchase Plan, and changes to its equity incentive plan.
Investors and observers who follow ADTX news can use this stream of press releases and related filings to track how Aditxt describes the progress of its platform strategy, its health-focused programs, its relationships with companies such as Evofem Biosciences, and its ongoing corporate and capital structure actions. Returning to this page provides a way to review the company’s official communications over time.
Aditxt (ADTX) has announced plans to establish a new high-capacity AditxtScore™ Center in Richmond, VA, with an investment of $31.5 million over three years. This facility aims to enhance the processing capacity for AditxtScore™, which evaluates immune health by analyzing biomarkers. The center will create over 300 new jobs and is expected to deliver up to 10 million reports annually. This initiative aligns with the company's strategic vision to shift towards proactive immune health monitoring and follows the recent commercialization of the AditxtScore™ for COVID-19.
Aditxt Therapeutics (Nasdaq: ADTX) announced the appointment of Sunny Uberoi as its first Chief Communications Officer. Uberoi will enhance corporate communications and investor relations as the company prepares for its first-in-human clinical trials and the expansion of its AditxtScore platform, aimed at providing comprehensive immune system profiles. His previous experience includes roles at Bristol Myers Squibb, Deloitte, and Pfizer, positioning him to support Aditxt's growth strategy focused on immune health technologies.
Aditxt Therapeutics (Nasdaq: ADTX) announced a partnership with HealthBar to offer AditxtScore™ for COVID-19 immunity monitoring in Michigan. HealthBar provides on-demand healthcare services, including various COVID-19 testing options. AditxtScore™ will enhance HealthBar's current offerings by providing critical immunity status information. This collaboration aims to support businesses and schools as they reopen. Both CEOs emphasize the importance of effective testing options and the role of immune monitoring in understanding COVID-19 immunity levels.
Aditx Therapeutics (Nasdaq: ADTX) announced a partnership with Collection Sites, LLC, a subsidiary of Medivolve (OTC:COPRF), to offer AditxtScore™ for COVID-19 immunity monitoring through mobile testing centers. This service will engage existing personnel without requiring additional investment. All specimens will be processed at Aditxt's CLIA-certified center. The partnership aims to enhance testing accessibility as vaccination efforts progress in the U.S., with expectations that this service will generate significant revenue moving forward.
Aditxt Therapeutics, Inc. (ADTX) announced plans to initiate First-In-Human clinical trials for its psoriasis treatment utilizing the Apoptotic DNA Immunotherapy™ (ADi™) technology, aimed at reprogramming the immune system. These trials are set to commence in Q4 2021, following regulatory submission processes in Germany. ADi™ has shown promise in pre-clinical models, demonstrating reductions in skin thickening associated with psoriasis. The agreement with a regulatory consultant is a significant step toward advancing this therapeutic program.
Aditxt Therapeutics, Inc. (ADTX) announced a partnership with Eazy Testing Inc. to offer AditxtScore™ for COVID-19 at Eazy Testing's locations in California. This immune monitoring service supplements Eazy Testing’s existing COVID-19 testing options, providing clients with valuable information about their immunity status. Both companies anticipate that this initiative will enhance demand for immunity testing as part of the ongoing pandemic response. Aditxt focuses on developing technologies to improve immune health.
Aditx Therapeutics (Nasdaq: ADTX) announced the appointment of Dr. Dolly B. Tyan as Senior Vice President of Clinical Development – Transplantation. Dr. Tyan will spearhead the company's organ rejection therapeutic program, advancing candidates toward clinical trials and developing new products. She brings over 45 years of experience in transplantation, having contributed to landmark technologies in the field. Her initial focus will be on Aditxt's Apoptotic DNA Immunotherapy™ (ADi™) for skin allografts. Aditxt aims for breakthroughs in organ acceptance and reducing transplant rejection.
Aditx Therapeutics (ADTX) announced a financing deal with an institutional investor, projected to net approximately $4.5 million. This funding aims to enhance the AditxtScore™ immune monitoring service and support general corporate needs. The investor will purchase a $6.0 million convertible promissory note, convertible at $4.00 per share, with repayments starting in July 2021. Additionally, Aditx raised $3.3 million from warrant exercises. CEO Amro Albanna emphasized that this funding will help meet the growing demand for immune monitoring services amid rising COVID-19 cases.
Aditx Therapeutics (ADTX) announced the launch of the AditxtScore™ Immune Monitoring Platform effective February 1, 2021. This platform includes AditxtScore™ for COVID-19, designed to assess an individual's infection and immunity status against SARS-CoV-2. The test will evaluate the virus's presence and measure antibody levels for neutralization. Aditxt plans to offer this as a Lab Developed Test (LDT) through CLIA-certified reference labs, enabling channel partners to efficiently integrate the service without extra resources.
Aditxt Therapeutics has announced a distribution agreement with Todos Medical for its AditxtScore™ for COVID-19. This service, which aims to monitor immunity against SARS-CoV-2, is expected to be available in January 2021. Todos Medical will manage blood sample collection and processing at Aditxt's CLIA-accredited center. AditxtScore™ will evaluate both antibody and neutralizing antibodies, with plans to expand into T-cell and B-cell assessments, making it a comprehensive immune profiling tool as vaccine rollouts increase. This agreement marks a significant commercial step for Aditxt.